MarketBeat
23 Jul 2026, 23:06 UTC · 8w ago
Verdict
Headline takes no side. We score EW +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Edwards Lifesciences raised its full-year 2026 total company sales growth outlook to 10%–11%, up from 9%–11%.
So whatRaising the floor of annual revenue guidance typically signals strong operational momentum and increases investor confidence in growth trajectory.
More positive than 91% of claims this week
TMTT sales grew 44.8% year-over-year, with the company raising full-year TMTT sales guidance to $760 million–$780 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 84% of claims this week
The company expects its 2026 effective tax rate to be at the high end of the 16% to 19% range due to Pillar Two impacts and California R&D credit limitations.
More negative than 73% of claims this week
Edwards now expects gross margin to be at the lower end of its full-year 78% to 79% guidance.
More negative than 67% of claims this week
TAVR sales grew 10.5% to $1.3 billion in Q2, leading to an increase in full-year TAVR sales growth guidance to 8%–9%.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company reported stronger-than-expected Q2 results, raised full-year sales growth outlooks for the total company and multiple product lines, and showed strong growth in TMTT and TAVR.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
20h ago
+5.4%
Price agrees with the score
$88.35 vs $83.82 close before publication (Jul 23) · not market-adjusted
EW chart →
